Bukwang Pharm (003000)

Seoul

Currency in KRW

Disclaimer

5,030

-30(-0.59%)

Closed10/10

Fair Value

Day's Range

5,030

5,130

52 wk Range

4,470

9,000

003000 Income Statement

Featured here, the Income Statement (earnings report) for Bukwang Pharm, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

168,193.62

169,659.75

182,491.22

190,909.36

125,928.24

Total Revenues Growth

-13.4%

+0.87%

+7.56%

+4.61%

-34.04%

Cost Of Revenues

84,841.78

98,318.64

106,941.63

111,762.6

79,012.32

Gross Profit

83,351.84

71,341.12

75,549.59

79,146.77

46,915.92

Gross Profit Growth

-27.2%

-14.41%

+5.9%

+4.76%

-40.72%

Gross Profit Margin %

49.56%

42.05%

41.4%

41.46%

37.26%

Other Operating Expenses, Total

73,814.41

67,312.97

69,927.71

79,377.4

84,412.68

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-7%	-8.81%	+3.88%	+13.51%	+6.34%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	17,312.23	18,032.4	22,464.64	24,274.42	34,551.21
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	54,192.82	46,636.24	45,170.48	52,698.48	46,377.14
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,242.1	1,563	1,317.25	1,345.2	2,078.39

Operating Income

9,537.43

4,028.15

5,621.88

-230.64

-37,496.76

Operating Income Growth

-72.85%

-57.76%

+39.56%

-104.1%

-16,158.01%

EBIT Margin %

5.67%

2.37%

3.08%

-0.12%

-29.78%

Net Interest Expenses

1,963.79

-201.78

-1,140.16

-320.33

-727.77

Net Interest Expenses Growth

-71.83%

-110.27%

-465.06%

+71.91%

-127.2%

Interest Expense, Total

-90.85

-1,514.67

-1,408.31

-1,760.3

-3,807.57

Interest And Investment Income

2,054.64

1,312.89

268.16

1,439.98

3,079.81

Other Non Operating Expenses, Total

-1,075.85

-5,344.51

-1,004.97

33.31

-811.1

EBT, Excl. Unusual Items

10,425.36

-1,518.14

3,476.76

-517.65

-39,035.63

Gain (Loss) On Sale Of Assets

3.42

54.25

220.05

52.25

30.64

Other Unusual Items, Total

-

-3,538.5

-

-

-

EBT, Incl. Unusual Items

-1,361.81

-8,299.64

3,787.33

-1,032.87

-39,569.39

EBT, Incl. Unusual Items Growth

-100.71%

-509.46%

+145.63%

-127.27%

-3,731%

EBT, Incl. Unusual Items Margin

-0.81%

-4.89%

2.08%

-0.54%

-31.42%

Income Tax Expense

6,073.03

1,805.02

6,584.13

3,215.8

-5,162.87

Net Income to Company

-7,434.84

-10,104.66

-2,796.8

-4,248.68

-34,406.51

Minority Interest

22.48

2,901.66

1,880.18

1,773.82

3,076.85

Net Income

-7,412.37

-7,203

-916.62

-2,474.85

-31,329.66

Net Income Growth

-105.09%

+2.82%

+87.27%

-170%

-1,165.92%

Net Income Margin %

-4.41%

-4.25%

-0.5%

-1.3%

-24.88%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

-7,412.37

-7,203

-916.62

-2,474.85

-31,329.66

Basic EPS - Continuing Operations

-103.43

-104.95

-13.39

-36.15

-457.67

Basic EPS - Continuing Operations Growth

-105.16%

-1.48%

+87.24%

-170.02%

-1,165.92%

Diluted EPS - Continuing Operations

-103.64

-105

-13.39

-36.15

-458

Diluted EPS - Continuing Operations Growth

-105.17%

-1.32%

+87.25%

-170.02%

-1,166.83%

Basic Weighted Average Shares Outstanding

71.67

68.63

68.46

68.45

68.45

Diluted Weighted Average Shares Outstanding

71.67

68.63

68.46

68.45

68.45

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

15,377.05

10,185.95

10,464.64

4,885.89

-33,204.32

EBITDA Growth

-63.39%

-33.76%

+2.74%

-53.31%

-779.6%

EBITDA Margin %

9.14%

6%

5.73%

2.56%

-26.37%

EBIT

9,537.43

4,028.15

5,621.88

-230.64

-37,496.76

* In Millions of KRW (except for per share items)